Paula Roberson
Concepts (399)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Stroke | 6 | 2019 | 526 | 0.860 |
Why?
| Fluorocarbons | 3 | 2019 | 52 | 0.620 |
Why?
| Cerebral Angiography | 4 | 2012 | 106 | 0.560 |
Why?
| Cognition Disorders | 6 | 2011 | 240 | 0.450 |
Why?
| Vision Tests | 1 | 2011 | 16 | 0.410 |
Why?
| Apnea | 1 | 2011 | 20 | 0.410 |
Why?
| Mydriatics | 1 | 2011 | 14 | 0.410 |
Why?
| Retinopathy of Prematurity | 1 | 2011 | 17 | 0.400 |
Why?
| Tissue Plasminogen Activator | 5 | 2022 | 124 | 0.390 |
Why?
| Osteoblasts | 7 | 2014 | 514 | 0.390 |
Why?
| Disease Models, Animal | 3 | 2012 | 1647 | 0.370 |
Why?
| Patient Care Planning | 2 | 2010 | 79 | 0.370 |
Why?
| Bone and Bones | 6 | 2013 | 515 | 0.370 |
Why?
| Energy Intake | 4 | 2016 | 196 | 0.350 |
Why?
| Pleural Effusion | 2 | 2022 | 38 | 0.350 |
Why?
| Apoptosis | 8 | 2014 | 1302 | 0.330 |
Why?
| Aged | 22 | 2021 | 10060 | 0.330 |
Why?
| Aging | 5 | 2014 | 784 | 0.320 |
Why?
| Warts | 2 | 2005 | 23 | 0.320 |
Why?
| Antigens, Fungal | 2 | 2005 | 31 | 0.320 |
Why?
| Microbubbles | 4 | 2011 | 34 | 0.320 |
Why?
| Antigens, Viral | 2 | 2005 | 58 | 0.320 |
Why?
| Alzheimer Disease | 4 | 2018 | 369 | 0.310 |
Why?
| Nursing Research | 2 | 2009 | 49 | 0.310 |
Why?
| Apathy | 2 | 2018 | 47 | 0.300 |
Why?
| Parathyroid Hormone | 4 | 2010 | 196 | 0.290 |
Why?
| Bone Density | 8 | 2014 | 416 | 0.280 |
Why?
| Immunotherapy | 2 | 2005 | 264 | 0.270 |
Why?
| Trichophyton | 1 | 2005 | 6 | 0.270 |
Why?
| Prospective Studies | 13 | 2022 | 2606 | 0.260 |
Why?
| Hospitalization | 2 | 2016 | 704 | 0.260 |
Why?
| Activities of Daily Living | 5 | 2017 | 204 | 0.260 |
Why?
| Mumps virus | 1 | 2005 | 19 | 0.260 |
Why?
| Patient-Centered Care | 1 | 2007 | 132 | 0.260 |
Why?
| Tai Ji | 3 | 2011 | 38 | 0.260 |
Why?
| Veterans | 3 | 2023 | 619 | 0.260 |
Why?
| Behavior Therapy | 1 | 2007 | 203 | 0.260 |
Why?
| Osteocytes | 3 | 2014 | 219 | 0.250 |
Why?
| Candida | 1 | 2005 | 67 | 0.250 |
Why?
| Female | 35 | 2021 | 28471 | 0.250 |
Why?
| Ultrasonic Therapy | 3 | 2011 | 40 | 0.250 |
Why?
| Oxidative Stress | 5 | 2013 | 958 | 0.250 |
Why?
| Nutrition Assessment | 3 | 2016 | 80 | 0.240 |
Why?
| Rabbits | 4 | 2012 | 425 | 0.240 |
Why?
| Glucocorticoids | 3 | 2011 | 234 | 0.240 |
Why?
| Brain Ischemia | 2 | 2019 | 169 | 0.240 |
Why?
| Male | 32 | 2019 | 27347 | 0.240 |
Why?
| Geriatric Assessment | 7 | 2012 | 126 | 0.240 |
Why?
| Health Promotion | 1 | 2007 | 300 | 0.240 |
Why?
| Patient Education as Topic | 1 | 2007 | 311 | 0.240 |
Why?
| Osteogenesis | 6 | 2013 | 377 | 0.230 |
Why?
| Thrombolytic Therapy | 3 | 2022 | 127 | 0.230 |
Why?
| Body Weight | 2 | 2012 | 578 | 0.230 |
Why?
| Protein-Energy Malnutrition | 1 | 2002 | 16 | 0.220 |
Why?
| Humans | 42 | 2023 | 54391 | 0.220 |
Why?
| Empyema, Pleural | 1 | 2022 | 12 | 0.210 |
Why?
| Severity of Illness Index | 7 | 2017 | 1082 | 0.210 |
Why?
| Frail Elderly | 3 | 2007 | 32 | 0.200 |
Why?
| Fibrinolytic Agents | 3 | 2022 | 139 | 0.200 |
Why?
| Nursing Evaluation Research | 3 | 2010 | 47 | 0.200 |
Why?
| Academic Medical Centers | 2 | 2013 | 146 | 0.200 |
Why?
| Exercise Therapy | 2 | 2017 | 123 | 0.200 |
Why?
| Pilot Projects | 6 | 2018 | 807 | 0.200 |
Why?
| Estrogen Receptor alpha | 2 | 2013 | 95 | 0.200 |
Why?
| Inflammation | 3 | 2012 | 678 | 0.190 |
Why?
| Mortality | 3 | 2007 | 102 | 0.190 |
Why?
| Animals | 19 | 2014 | 14409 | 0.190 |
Why?
| Cerebral Hemorrhage | 2 | 2011 | 105 | 0.190 |
Why?
| Dermatology | 1 | 2021 | 72 | 0.180 |
Why?
| Prenatal Exposure Delayed Effects | 1 | 2021 | 172 | 0.180 |
Why?
| Cannabis | 1 | 2021 | 149 | 0.170 |
Why?
| Double-Blind Method | 6 | 2019 | 743 | 0.160 |
Why?
| Coronary Artery Disease | 1 | 2002 | 329 | 0.160 |
Why?
| Neuroprotective Agents | 1 | 2019 | 125 | 0.160 |
Why?
| Cognition | 3 | 2018 | 350 | 0.160 |
Why?
| Research Design | 3 | 2010 | 375 | 0.160 |
Why?
| Treatment Outcome | 9 | 2019 | 5612 | 0.160 |
Why?
| Rehabilitation Centers | 3 | 2012 | 37 | 0.160 |
Why?
| Weight Gain | 2 | 2012 | 244 | 0.150 |
Why?
| Osteoarthritis, Knee | 2 | 2009 | 104 | 0.150 |
Why?
| Nutritional Status | 4 | 2012 | 158 | 0.150 |
Why?
| Sensation Disorders | 1 | 2017 | 14 | 0.150 |
Why?
| Weight Loss | 2 | 2012 | 271 | 0.150 |
Why?
| Transcranial Magnetic Stimulation | 1 | 2018 | 81 | 0.150 |
Why?
| Aged, 80 and over | 10 | 2017 | 3431 | 0.150 |
Why?
| Chest Tubes | 1 | 2016 | 23 | 0.140 |
Why?
| Bone Remodeling | 4 | 2014 | 176 | 0.140 |
Why?
| Methylphenidate | 1 | 2017 | 94 | 0.140 |
Why?
| Diabetes Mellitus, Type 2 | 2 | 2013 | 486 | 0.140 |
Why?
| Recovery of Function | 2 | 2019 | 222 | 0.140 |
Why?
| Postural Balance | 1 | 2017 | 61 | 0.140 |
Why?
| Arkansas | 6 | 2019 | 2100 | 0.140 |
Why?
| Fear | 1 | 2017 | 87 | 0.140 |
Why?
| Pandemics | 1 | 2021 | 594 | 0.140 |
Why?
| Nursing Assessment | 4 | 2010 | 64 | 0.140 |
Why?
| Nursing Homes | 2 | 2009 | 126 | 0.140 |
Why?
| Health Status | 2 | 2011 | 368 | 0.140 |
Why?
| Accidental Falls | 1 | 2017 | 98 | 0.130 |
Why?
| Internship and Residency | 1 | 2021 | 501 | 0.130 |
Why?
| Ultrasonography, Interventional | 1 | 2016 | 146 | 0.130 |
Why?
| Pneumonia | 1 | 2016 | 129 | 0.130 |
Why?
| Heart Defects, Congenital | 1 | 2021 | 608 | 0.130 |
Why?
| Central Nervous System Stimulants | 1 | 2017 | 255 | 0.120 |
Why?
| C-Reactive Protein | 3 | 2012 | 159 | 0.120 |
Why?
| Osteoclasts | 4 | 2013 | 469 | 0.120 |
Why?
| Prednisolone | 2 | 2011 | 57 | 0.120 |
Why?
| Cerebrovascular Circulation | 2 | 2013 | 137 | 0.120 |
Why?
| Statistics, Nonparametric | 2 | 2011 | 232 | 0.120 |
Why?
| Brain | 2 | 2013 | 1392 | 0.120 |
Why?
| Serum Albumin | 3 | 2012 | 62 | 0.120 |
Why?
| Mice | 11 | 2014 | 6428 | 0.120 |
Why?
| bcl-2 Homologous Antagonist-Killer Protein | 1 | 2014 | 22 | 0.120 |
Why?
| bcl-2-Associated X Protein | 1 | 2014 | 73 | 0.120 |
Why?
| Biostatistics | 1 | 2013 | 6 | 0.120 |
Why?
| Patient Discharge | 3 | 2023 | 353 | 0.110 |
Why?
| Personnel Management | 1 | 2013 | 21 | 0.110 |
Why?
| Hospital Units | 1 | 2012 | 13 | 0.110 |
Why?
| Vasodilation | 1 | 2013 | 106 | 0.110 |
Why?
| Random Allocation | 2 | 2011 | 312 | 0.110 |
Why?
| Intracranial Embolism | 1 | 2012 | 28 | 0.110 |
Why?
| Prealbumin | 2 | 2012 | 24 | 0.110 |
Why?
| Wnt Signaling Pathway | 1 | 2013 | 94 | 0.110 |
Why?
| Physical Endurance | 1 | 2012 | 49 | 0.110 |
Why?
| Forkhead Transcription Factors | 1 | 2013 | 118 | 0.110 |
Why?
| Time Factors | 7 | 2019 | 3210 | 0.110 |
Why?
| Cell Nucleus | 1 | 2013 | 203 | 0.110 |
Why?
| Leg | 1 | 2012 | 130 | 0.110 |
Why?
| Data Interpretation, Statistical | 2 | 2010 | 177 | 0.110 |
Why?
| Health Services Research | 1 | 2013 | 165 | 0.110 |
Why?
| Edema | 1 | 2012 | 74 | 0.100 |
Why?
| Hypoglycemic Agents | 1 | 2013 | 177 | 0.100 |
Why?
| Emulsions | 1 | 2011 | 27 | 0.100 |
Why?
| Malnutrition | 1 | 2012 | 82 | 0.100 |
Why?
| Intensive Care, Neonatal | 1 | 2011 | 24 | 0.100 |
Why?
| Osteoprotegerin | 1 | 2011 | 57 | 0.100 |
Why?
| Cell Adhesion Molecules | 1 | 2011 | 87 | 0.100 |
Why?
| Hospitals, Veterans | 3 | 2008 | 125 | 0.100 |
Why?
| Chi-Square Distribution | 1 | 2011 | 318 | 0.100 |
Why?
| Estrogens | 2 | 2010 | 244 | 0.100 |
Why?
| Sclerotherapy | 1 | 2011 | 47 | 0.100 |
Why?
| Insulin | 1 | 2013 | 511 | 0.100 |
Why?
| Face | 1 | 2011 | 66 | 0.100 |
Why?
| Randomized Controlled Trials as Topic | 3 | 2009 | 594 | 0.090 |
Why?
| Genetic Techniques | 1 | 2010 | 15 | 0.090 |
Why?
| Mice, Inbred C57BL | 6 | 2013 | 2001 | 0.090 |
Why?
| Muscle, Skeletal | 2 | 2007 | 847 | 0.090 |
Why?
| Middle Aged | 10 | 2019 | 13082 | 0.090 |
Why?
| Dietary Proteins | 1 | 2012 | 230 | 0.090 |
Why?
| Weight Lifting | 2 | 2007 | 31 | 0.090 |
Why?
| Case-Control Studies | 4 | 2021 | 1229 | 0.090 |
Why?
| Sound | 1 | 2009 | 11 | 0.090 |
Why?
| Statistics as Topic | 1 | 2010 | 102 | 0.090 |
Why?
| Neovascularization, Physiologic | 1 | 2009 | 72 | 0.090 |
Why?
| Water | 1 | 2009 | 103 | 0.090 |
Why?
| Vascular Malformations | 1 | 2011 | 101 | 0.090 |
Why?
| Alendronate | 1 | 2009 | 20 | 0.090 |
Why?
| Premature Birth | 1 | 2011 | 154 | 0.090 |
Why?
| Logistic Models | 2 | 2021 | 991 | 0.090 |
Why?
| Vascular Surgical Procedures | 1 | 2011 | 178 | 0.080 |
Why?
| Periosteum | 1 | 2008 | 20 | 0.080 |
Why?
| Multienzyme Complexes | 2 | 2010 | 41 | 0.080 |
Why?
| Femur | 3 | 2014 | 144 | 0.080 |
Why?
| Pain | 2 | 2009 | 405 | 0.080 |
Why?
| Nonverbal Communication | 1 | 2008 | 17 | 0.080 |
Why?
| Injections, Intralesional | 2 | 2005 | 38 | 0.080 |
Why?
| Mitosis | 1 | 2008 | 106 | 0.080 |
Why?
| Verbal Behavior | 1 | 2008 | 35 | 0.080 |
Why?
| Nocturnal Myoclonus Syndrome | 1 | 2008 | 14 | 0.080 |
Why?
| Osteoarthritis | 1 | 2008 | 69 | 0.080 |
Why?
| Bone Density Conservation Agents | 1 | 2009 | 82 | 0.080 |
Why?
| Patient Selection | 1 | 2009 | 284 | 0.080 |
Why?
| Gonadal Steroid Hormones | 1 | 2007 | 42 | 0.080 |
Why?
| Nursing Theory | 1 | 2007 | 6 | 0.080 |
Why?
| Independent Living | 2 | 2017 | 46 | 0.070 |
Why?
| Controlled Clinical Trials as Topic | 1 | 2007 | 21 | 0.070 |
Why?
| Psychological Theory | 1 | 2007 | 25 | 0.070 |
Why?
| Megestrol Acetate | 1 | 2007 | 17 | 0.070 |
Why?
| Pain Measurement | 1 | 2008 | 248 | 0.070 |
Why?
| Cell Differentiation | 1 | 2010 | 720 | 0.070 |
Why?
| Cerebellum | 1 | 2008 | 142 | 0.070 |
Why?
| Child | 5 | 2022 | 7368 | 0.070 |
Why?
| Radiology, Interventional | 1 | 2007 | 35 | 0.070 |
Why?
| Cohort Studies | 3 | 2012 | 1546 | 0.070 |
Why?
| Phosphorylation | 4 | 2010 | 613 | 0.070 |
Why?
| Cells, Cultured | 4 | 2013 | 1737 | 0.070 |
Why?
| Muscle Strength | 1 | 2007 | 132 | 0.070 |
Why?
| Hypoalbuminemia | 1 | 2005 | 5 | 0.070 |
Why?
| Histocompatibility Antigens | 1 | 2005 | 6 | 0.070 |
Why?
| Evidence-Based Medicine | 1 | 2007 | 276 | 0.070 |
Why?
| Transcription Factors | 2 | 2013 | 622 | 0.070 |
Why?
| Ethanol | 1 | 2008 | 323 | 0.070 |
Why?
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2005 | 75 | 0.070 |
Why?
| Interferon-alpha | 1 | 2005 | 50 | 0.070 |
Why?
| Adult | 6 | 2021 | 14207 | 0.060 |
Why?
| Testosterone | 1 | 2005 | 119 | 0.060 |
Why?
| Polysomnography | 3 | 2009 | 71 | 0.060 |
Why?
| Papillomaviridae | 1 | 2005 | 107 | 0.060 |
Why?
| Prognosis | 3 | 2005 | 2126 | 0.060 |
Why?
| Social Support | 1 | 2007 | 297 | 0.060 |
Why?
| Health Behavior | 1 | 2007 | 275 | 0.060 |
Why?
| Intracranial Thrombosis | 1 | 2004 | 22 | 0.060 |
Why?
| Monocytes | 1 | 2005 | 156 | 0.060 |
Why?
| Cell Division | 1 | 2005 | 330 | 0.060 |
Why?
| Reactive Oxygen Species | 3 | 2013 | 491 | 0.060 |
Why?
| Cytokines | 1 | 2007 | 677 | 0.060 |
Why?
| Infant | 3 | 2021 | 3829 | 0.060 |
Why?
| Walking | 2 | 2017 | 110 | 0.060 |
Why?
| Mental Status Schedule | 2 | 2017 | 19 | 0.060 |
Why?
| Retrospective Studies | 3 | 2022 | 6459 | 0.060 |
Why?
| Antiviral Agents | 1 | 2005 | 188 | 0.060 |
Why?
| Infant, Newborn | 1 | 2011 | 2923 | 0.060 |
Why?
| Cysteine Endopeptidases | 1 | 2003 | 75 | 0.060 |
Why?
| Agricultural Workers' Diseases | 1 | 2003 | 7 | 0.060 |
Why?
| Aircraft | 1 | 2003 | 12 | 0.060 |
Why?
| Recombinant Proteins | 1 | 2005 | 570 | 0.060 |
Why?
| Pesticides | 1 | 2003 | 22 | 0.060 |
Why?
| Young Adult | 3 | 2022 | 4318 | 0.060 |
Why?
| Pediatrics | 1 | 2007 | 323 | 0.060 |
Why?
| Albumins | 1 | 2003 | 39 | 0.060 |
Why?
| Diet Records | 2 | 2016 | 24 | 0.060 |
Why?
| Arteriovenous Shunt, Surgical | 1 | 2003 | 38 | 0.050 |
Why?
| Aftercare | 1 | 2023 | 82 | 0.050 |
Why?
| Platelet Aggregation Inhibitors | 1 | 2004 | 179 | 0.050 |
Why?
| Atrophy | 2 | 2013 | 40 | 0.050 |
Why?
| Personnel Selection | 1 | 2021 | 28 | 0.050 |
Why?
| Occupational Exposure | 1 | 2003 | 129 | 0.050 |
Why?
| Follow-Up Studies | 3 | 2017 | 2390 | 0.050 |
Why?
| Skin Diseases | 1 | 2003 | 141 | 0.050 |
Why?
| Videoconferencing | 1 | 2021 | 40 | 0.050 |
Why?
| Contrast Media | 1 | 2003 | 221 | 0.050 |
Why?
| Signal Transduction | 2 | 2010 | 1752 | 0.050 |
Why?
| Schools, Medical | 1 | 2021 | 82 | 0.050 |
Why?
| Exercise | 1 | 2005 | 552 | 0.050 |
Why?
| Neoplasm Proteins | 1 | 2003 | 360 | 0.050 |
Why?
| Shc Signaling Adaptor Proteins | 2 | 2010 | 27 | 0.050 |
Why?
| Ovariectomy | 2 | 2013 | 127 | 0.050 |
Why?
| Thrombosis | 1 | 2003 | 243 | 0.050 |
Why?
| Stem Cells | 2 | 2013 | 194 | 0.040 |
Why?
| Maximum Tolerated Dose | 1 | 2019 | 37 | 0.040 |
Why?
| Administration, Intravenous | 1 | 2019 | 75 | 0.040 |
Why?
| Neuropsychological Tests | 2 | 2013 | 363 | 0.040 |
Why?
| Asthma | 1 | 2003 | 293 | 0.040 |
Why?
| Disability Evaluation | 1 | 2019 | 103 | 0.040 |
Why?
| Drug Administration Schedule | 1 | 2019 | 401 | 0.040 |
Why?
| Ultrasonography, Doppler, Transcranial | 2 | 2011 | 26 | 0.040 |
Why?
| Child, Preschool | 3 | 2016 | 4158 | 0.040 |
Why?
| Diet | 2 | 2016 | 598 | 0.040 |
Why?
| Cell Proliferation | 2 | 2013 | 1097 | 0.040 |
Why?
| Risk Factors | 2 | 2021 | 3937 | 0.040 |
Why?
| Cell Line | 2 | 2011 | 1152 | 0.040 |
Why?
| Hypertension | 1 | 2002 | 565 | 0.040 |
Why?
| Cross-Over Studies | 1 | 2018 | 250 | 0.040 |
Why?
| Calcium | 2 | 2014 | 434 | 0.040 |
Why?
| Executive Function | 1 | 2018 | 80 | 0.040 |
Why?
| Smoking | 1 | 2021 | 552 | 0.040 |
Why?
| Food Service, Hospital | 1 | 2016 | 4 | 0.040 |
Why?
| Antioxidants | 2 | 2010 | 297 | 0.040 |
Why?
| Photography | 1 | 2016 | 39 | 0.040 |
Why?
| Video Recording | 1 | 2017 | 90 | 0.040 |
Why?
| Risk Assessment | 1 | 2021 | 1362 | 0.040 |
Why?
| Models, Genetic | 2 | 2010 | 209 | 0.040 |
Why?
| Length of Stay | 2 | 2011 | 683 | 0.040 |
Why?
| Drainage | 1 | 2016 | 79 | 0.040 |
Why?
| Meals | 1 | 2016 | 62 | 0.030 |
Why?
| Ultrasonography | 2 | 2011 | 486 | 0.030 |
Why?
| Blotting, Western | 2 | 2010 | 684 | 0.030 |
Why?
| Transcription, Genetic | 2 | 2010 | 418 | 0.030 |
Why?
| Adolescent | 3 | 2016 | 6900 | 0.030 |
Why?
| Caregivers | 1 | 2017 | 241 | 0.030 |
Why?
| United States | 2 | 2021 | 5208 | 0.030 |
Why?
| Inpatients | 1 | 2016 | 206 | 0.030 |
Why?
| Combined Modality Therapy | 1 | 2016 | 693 | 0.030 |
Why?
| Porosity | 1 | 2014 | 34 | 0.030 |
Why?
| Magnetic Resonance Imaging | 2 | 2011 | 1616 | 0.030 |
Why?
| Administration, Intranasal | 1 | 2013 | 29 | 0.030 |
Why?
| Pregnancy | 1 | 2021 | 2639 | 0.030 |
Why?
| Mice, 129 Strain | 1 | 2013 | 49 | 0.030 |
Why?
| Gene Knockout Techniques | 1 | 2013 | 45 | 0.030 |
Why?
| Magnetic Resonance Angiography | 1 | 2013 | 80 | 0.030 |
Why?
| Adipogenesis | 1 | 2013 | 54 | 0.030 |
Why?
| Intermediate Care Facilities | 1 | 2012 | 6 | 0.030 |
Why?
| Cross-Sectional Studies | 2 | 2009 | 1696 | 0.030 |
Why?
| Professional Competence | 1 | 2013 | 47 | 0.030 |
Why?
| Memory | 1 | 2013 | 124 | 0.030 |
Why?
| Swine | 2 | 2004 | 430 | 0.030 |
Why?
| Regional Blood Flow | 1 | 2012 | 121 | 0.030 |
Why?
| Homeostasis | 1 | 2014 | 223 | 0.030 |
Why?
| Professional Role | 1 | 2013 | 88 | 0.030 |
Why?
| Organ Size | 1 | 2013 | 237 | 0.030 |
Why?
| Reproducibility of Results | 1 | 2016 | 1301 | 0.030 |
Why?
| Models, Biological | 2 | 2008 | 825 | 0.030 |
Why?
| Uterus | 1 | 2013 | 100 | 0.030 |
Why?
| Depression | 1 | 2017 | 596 | 0.030 |
Why?
| Spine | 1 | 2013 | 112 | 0.030 |
Why?
| Cell Cycle Proteins | 1 | 2013 | 198 | 0.030 |
Why?
| Adiposity | 1 | 2013 | 142 | 0.030 |
Why?
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2011 | 21 | 0.030 |
Why?
| Estradiol | 1 | 2013 | 219 | 0.030 |
Why?
| Immunoenzyme Techniques | 1 | 2011 | 166 | 0.020 |
Why?
| Mice, Transgenic | 1 | 2013 | 658 | 0.020 |
Why?
| Bone Marrow | 1 | 2013 | 414 | 0.020 |
Why?
| Interleukin-6 | 1 | 2012 | 315 | 0.020 |
Why?
| Arthritis | 1 | 2011 | 49 | 0.020 |
Why?
| Arachidonate 15-Lipoxygenase | 1 | 2010 | 17 | 0.020 |
Why?
| Arachidonate 12-Lipoxygenase | 1 | 2010 | 17 | 0.020 |
Why?
| Veins | 1 | 2011 | 74 | 0.020 |
Why?
| Blood Loss, Surgical | 1 | 2011 | 79 | 0.020 |
Why?
| Physical Fitness | 1 | 2011 | 69 | 0.020 |
Why?
| Tumor Necrosis Factor-alpha | 1 | 2012 | 435 | 0.020 |
Why?
| Smad1 Protein | 1 | 2010 | 6 | 0.020 |
Why?
| Glutathione Reductase | 1 | 2010 | 15 | 0.020 |
Why?
| Gene Knock-In Techniques | 1 | 2010 | 30 | 0.020 |
Why?
| Models, Nursing | 1 | 2010 | 21 | 0.020 |
Why?
| 11-beta-Hydroxysteroid Dehydrogenase Type 2 | 1 | 2009 | 12 | 0.020 |
Why?
| Phenotype | 1 | 2013 | 819 | 0.020 |
Why?
| Bone Morphogenetic Protein 2 | 1 | 2010 | 51 | 0.020 |
Why?
| False Positive Reactions | 1 | 2010 | 68 | 0.020 |
Why?
| Wnt Proteins | 1 | 2010 | 110 | 0.020 |
Why?
| Assisted Living Facilities | 1 | 2009 | 16 | 0.020 |
Why?
| Preoperative Care | 1 | 2011 | 184 | 0.020 |
Why?
| Extracellular Signal-Regulated MAP Kinases | 1 | 2010 | 101 | 0.020 |
Why?
| Nursing Staff | 1 | 2009 | 31 | 0.020 |
Why?
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2009 | 60 | 0.020 |
Why?
| Actigraphy | 1 | 2009 | 22 | 0.020 |
Why?
| Southeastern United States | 1 | 2009 | 55 | 0.020 |
Why?
| Analysis of Variance | 1 | 2011 | 634 | 0.020 |
Why?
| Enzyme Activation | 1 | 2010 | 328 | 0.020 |
Why?
| Databases, Genetic | 1 | 2010 | 101 | 0.020 |
Why?
| Stress, Mechanical | 1 | 2009 | 96 | 0.020 |
Why?
| Multicenter Studies as Topic | 1 | 2009 | 91 | 0.020 |
Why?
| Acid Phosphatase | 1 | 2009 | 15 | 0.020 |
Why?
| Research Subjects | 1 | 2009 | 57 | 0.020 |
Why?
| Thymidine Kinase | 1 | 2008 | 20 | 0.020 |
Why?
| Program Development | 1 | 2010 | 198 | 0.020 |
Why?
| Ganciclovir | 1 | 2008 | 35 | 0.020 |
Why?
| Vascular Endothelial Growth Factor A | 1 | 2009 | 232 | 0.020 |
Why?
| Data Collection | 1 | 2010 | 320 | 0.020 |
Why?
| Isoenzymes | 1 | 2009 | 177 | 0.020 |
Why?
| Discriminant Analysis | 1 | 2008 | 34 | 0.020 |
Why?
| Cell Count | 1 | 2008 | 181 | 0.020 |
Why?
| Program Evaluation | 1 | 2010 | 379 | 0.020 |
Why?
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 474 | 0.020 |
Why?
| Behavior | 1 | 2008 | 48 | 0.020 |
Why?
| Collagen Type I | 1 | 2008 | 97 | 0.020 |
Why?
| Mobility Limitation | 1 | 2008 | 25 | 0.020 |
Why?
| Postmenopause | 1 | 2009 | 102 | 0.020 |
Why?
| Feasibility Studies | 1 | 2009 | 398 | 0.020 |
Why?
| Linear Models | 1 | 2009 | 308 | 0.020 |
Why?
| Matrix Metalloproteinases | 1 | 2008 | 52 | 0.020 |
Why?
| Observer Variation | 1 | 2008 | 139 | 0.020 |
Why?
| Attitude to Health | 1 | 2009 | 226 | 0.020 |
Why?
| DNA Replication | 1 | 2008 | 152 | 0.020 |
Why?
| Motivation | 1 | 2009 | 289 | 0.020 |
Why?
| Androgens | 1 | 2007 | 68 | 0.020 |
Why?
| Electroencephalography | 1 | 2009 | 357 | 0.020 |
Why?
| Psychometrics | 1 | 2008 | 239 | 0.020 |
Why?
| Animals, Newborn | 1 | 2008 | 396 | 0.020 |
Why?
| Biopsy | 1 | 2009 | 692 | 0.020 |
Why?
| Proportional Hazards Models | 1 | 2007 | 430 | 0.020 |
Why?
| Algorithms | 1 | 2010 | 697 | 0.020 |
Why?
| Dose-Response Relationship, Drug | 1 | 2009 | 1476 | 0.020 |
Why?
| APACHE | 1 | 2004 | 24 | 0.020 |
Why?
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2004 | 34 | 0.020 |
Why?
| Prevalence | 1 | 2008 | 1025 | 0.020 |
Why?
| Gene Expression Profiling | 1 | 2010 | 1141 | 0.020 |
Why?
| Injections, Intravenous | 1 | 2004 | 148 | 0.020 |
Why?
| Predictive Value of Tests | 1 | 2007 | 1045 | 0.020 |
Why?
| Regression Analysis | 1 | 2005 | 445 | 0.020 |
Why?
| bcl-Associated Death Protein | 1 | 2003 | 13 | 0.010 |
Why?
| Receptor Activator of Nuclear Factor-kappa B | 1 | 2003 | 32 | 0.010 |
Why?
| Dactinomycin | 1 | 2003 | 23 | 0.010 |
Why?
| Culture Media, Conditioned | 1 | 2003 | 52 | 0.010 |
Why?
| Core Binding Factor Alpha 1 Subunit | 1 | 2003 | 48 | 0.010 |
Why?
| Cyclic AMP Response Element-Binding Protein | 1 | 2003 | 34 | 0.010 |
Why?
| Rats, Sprague-Dawley | 1 | 2008 | 1664 | 0.010 |
Why?
| Body Mass Index | 1 | 2007 | 712 | 0.010 |
Why?
| Cyclic AMP-Dependent Protein Kinases | 1 | 2003 | 56 | 0.010 |
Why?
| Mumps | 1 | 2003 | 18 | 0.010 |
Why?
| Microspheres | 1 | 2003 | 34 | 0.010 |
Why?
| Spirometry | 1 | 2003 | 30 | 0.010 |
Why?
| Respiratory Function Tests | 1 | 2003 | 98 | 0.010 |
Why?
| Dogs | 1 | 2003 | 216 | 0.010 |
Why?
| HeLa Cells | 1 | 2003 | 291 | 0.010 |
Why?
| Proteasome Endopeptidase Complex | 1 | 2003 | 131 | 0.010 |
Why?
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2003 | 158 | 0.010 |
Why?
| RNA | 1 | 2003 | 202 | 0.010 |
Why?
| Blood Vessel Prosthesis | 1 | 2003 | 97 | 0.010 |
Why?
| RANK Ligand | 1 | 2003 | 183 | 0.010 |
Why?
| Candidiasis | 1 | 2003 | 122 | 0.010 |
Why?
| Membrane Glycoproteins | 1 | 2003 | 270 | 0.010 |
Why?
| Glucose | 1 | 2004 | 366 | 0.010 |
Why?
| Kinetics | 1 | 2003 | 692 | 0.010 |
Why?
| Health Surveys | 1 | 2003 | 261 | 0.010 |
Why?
| Carrier Proteins | 1 | 2003 | 360 | 0.010 |
Why?
| Renal Dialysis | 1 | 2003 | 193 | 0.010 |
Why?
| Rats | 1 | 2008 | 3419 | 0.010 |
Why?
| Bone Resorption | 1 | 2003 | 328 | 0.010 |
Why?
| RNA, Messenger | 1 | 2003 | 1203 | 0.010 |
Why?
| Postoperative Complications | 1 | 2003 | 1035 | 0.010 |
Why?
|
|
Roberson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|